Remimazolam tosilate combined with flumazenil versus etomidate for procedural sedation in older men undergoing transperineal prostate biopsy: a prospective, participant- and outcome assessor-blinded, randomized controlled superiority trial

Abstract Background Procedural sedation for prostate biopsy in older patients requires effective sedation, cardiorespiratory safety, and rapid recovery. Etomidate provides hemodynamic stability but may cause myoclonus, injection pain, and postoperative nausea and vomiting, and lacks a specific antagonist. Remimazolam has rapid onset and metabolism and can be reversed with flumazenil. We compared remimazolam combined with flumazenil with etomidate in older men undergoing transperineal prostate biopsy. Methods This single-center, prospective, participant- and outcome assessor-blinded, randomized, parallel-group superiority trial enrolled older male patients undergoing transperineal prostate biopsy. Patients were randomized 1:1 to receive sufentanil-remimazolam followed by flumazenil or sufentanil-etomidate followed by equal-volume saline. The primary outcome was recovery time. Key secondary outcomes were 30-min postoperative change in Digit Symbol Substitution Test (DSST) score and incidences of hypoxemia, clinically relevant hypotension, and postoperative nausea and vomiting. One interim analysis with O’Brien-Fleming alpha spending was prespecified. Results Of 136 randomized patients, 130 were included in the interim primary outcome analysis, including 66 in the remimazolam group and 64 in the etomidate group. Recovery time was shorter with remimazolam than with etomidate [1.48 (1.15, 1.90) min vs. 6.61 (5.27, 8.03) min; P < 0.0001]. The Hodges-Lehmann median difference was 4.98 min (95% CI, 4.48 to 5.49), exceeding the prespecified superiority margin and meeting the efficacy stopping criterion. The 30-min DSST change did not differ significantly between groups. Hypoxemia was less frequent with remimazolam, although not statistically significant after Holm-Bonferroni adjustment. Postoperative nausea and vomiting was less frequent with remimazolam and remained significant after adjustment. No clinically relevant hypotension, serious adverse events, delayed recovery, or resedation occurred. Myoclonus and injection pain occurred only with etomidate. Conclusions Remimazolam combined with flumazenil significantly shortened recovery time without evidence of impaired early cognitive recovery in older men undergoing transperineal prostate biopsy. It was also associated with a lower incidence of postoperative nausea and vomiting and no observed increase in clinically relevant hypotension. Larger multicenter studies are warranted to confirm these findings. Trial registration Chinese Clinical Trial Registry, ChiCTR2400091993. Registered 7 November 2024.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-16
DOI
https://doi.org/10.21203/rs.3.rs-11134296/v1
Primary Topic
Anesthesia and Sedative Agents
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Remimazolam tosilate combined with flumazenil versus etomidate for procedural sedation in older men undergoing transperineal prostate biopsy: a prospective, participant- and outcome assessor-blinded, randomized controlled superiority trial

Pingyi Song, 裴磊磊, Xixi Wang, Yaomin Zhu et al.
3 links
Research Square
Anesthesia and Sedative Agents
preprint

Remimazolam tosilate combined with flumazenil versus etomidate for procedural sedation in older men undergoing transperineal prostate biopsy: a prospective, participant- and outcome assessor-blinded, randomized controlled superiority trial

Pingyi Song, 裴磊磊, Xixi Wang, Yaomin Zhu, Xinyan chen, Yansong Li, Hailiang Du, Tingting Yang
preprint en

Abstract

Abstract Background Procedural sedation for prostate biopsy in older patients requires effective sedation, cardiorespiratory safety, and rapid recovery. Etomidate provides hemodynamic stability but may cause myoclonus, injection pain, and postoperative nausea and vomiting, and lacks a specific antagonist. Remimazolam has rapid onset and metabolism and can be reversed with flumazenil. We compared remimazolam combined with flumazenil with etomidate in older men undergoing transperineal prostate biopsy. Methods This single-center, prospective, participant- and outcome assessor-blinded, randomized, parallel-group superiority trial enrolled older male patients undergoing transperineal prostate biopsy. Patients were randomized 1:1 to receive sufentanil-remimazolam followed by flumazenil or sufentanil-etomidate followed by equal-volume saline. The primary outcome was recovery time. Key secondary outcomes were 30-min postoperative change in Digit Symbol Substitution Test (DSST) score and incidences of hypoxemia, clinically relevant hypotension, and postoperative nausea and vomiting. One interim analysis with O’Brien-Fleming alpha spending was prespecified. Results Of 136 randomized patients, 130 were included in the interim primary outcome analysis, including 66 in the remimazolam group and 64 in the etomidate group. Recovery time was shorter with remimazolam than with etomidate [1.48 (1.15, 1.90) min vs. 6.61 (5.27, 8.03) min; P < 0.0001]. The Hodges-Lehmann median difference was 4.98 min (95% CI, 4.48 to 5.49), exceeding the prespecified superiority margin and meeting the efficacy stopping criterion. The 30-min DSST change did not differ significantly between groups. Hypoxemia was less frequent with remimazolam, although not statistically significant after Holm-Bonferroni adjustment. Postoperative nausea and vomiting was less frequent with remimazolam and remained significant after adjustment. No clinically relevant hypotension, serious adverse events, delayed recovery, or resedation occurred. Myoclonus and injection pain occurred only with etomidate. Conclusions Remimazolam combined with flumazenil significantly shortened recovery time without evidence of impaired early cognitive recovery in older men undergoing transperineal prostate biopsy. It was also associated with a lower incidence of postoperative nausea and vomiting and no observed increase in clinically relevant hypotension. Larger multicenter studies are warranted to confirm these findings. Trial registration Chinese Clinical Trial Registry, ChiCTR2400091993. Registered 7 November 2024.

Research Square
First Affiliated Hospital of Xi'an Jiaotong University (CN), Xi'an Jiaotong University (CN)
Good health and well-being
Anesthesia and Sedative Agents
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon